Jointown(SH:600998) Quan Jing Wang·2025-05-08 00:02Core Insights - The company, Jiuzhoutong, held a performance briefing on May 7, 2024, discussing its operational status, strategic transformation, and future plans with investors [1] - The B2C e-commerce segment, under the brand "Good Medicine Master," is expected to generate sales revenue of 980 million yuan in 2024, leveraging its extensive experience and user base [1] - Jiuzhoutong reported a total revenue of 151.81 billion yuan and a net profit attributable to shareholders of 2.507 billion yuan for 2024, reflecting a year-on-year revenue growth of 2.58% and a net profit growth of 39.88% [2] Company Performance - In 2024, Jiuzhoutong's B2C e-commerce business achieved a total sales GMV of over 1.57 billion yuan, with a significant year-on-year growth of 107.7% in interest e-commerce channels like Douyin and Kuaishou [2] - The company operates over 60 strategic partner brands and has launched more than 100 online flagship stores for well-known pharmaceutical and health brands [2] - For Q1 2025, Jiuzhoutong reported a revenue of 42.016 billion yuan, marking a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% increase compared to the same period last year [3]